The combination of the MTOR inhibitor rapamycin and proteasome inhibitor bortezomib is synergistic in vitro in multiple myeloma

被引：0
|
作者：
Leleu, X.
O'Sullivan, G.
Jia, X.
Ngo, H.
Moreau, A. S.
Roccaro, A.
Hatjiharisi, F.
Hideshima, T.
Anderson, K.
Ghobrial, I.
机构：
[1] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA
[2] CHRU, Immunol Lab, Serv Malad Sang, Lille, France
来源：
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL | 2007年 / 92卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：148 / 149
页数：2
相关论文
共 50 条
  • [1] The combination of the mTOR inhibitor rapamycin and proteasome inhibitor bortezomib is synergistic in vitro in multiple myeloma.
    O'Sullivan, Garrett
    Leleu, Xavier
    Jia, Xiaoying
    Hatjiharisi, Evdoxia
    Ngo, Hai
    Moreau, Anne-Sophie
    Tai, Yu-Tsu
    McMillin, Douglas
    Mitsiades, Constantine
    Raje, Noopur
    Hideshima, Teru
    Schlossman, Robert
    Richardson, Paul
    Munshi, Nikhil
    Anderson, Kenneth
    Ghobrial, Irene
    BLOOD, 2006, 108 (11) : 996A - 997A
  • [2] Combination of the mTOR inhibitor rapamycin and CC-5013 has synergistic activity in multiple myeloma
    Raje, N
    Kumar, S
    Hideshima, T
    Ishitsuka, K
    Chauhan, D
    Mitsiades, C
    Podar, K
    Le Gouill, S
    Richardson, P
    Munshi, NC
    Stirling, DI
    Antin, JH
    Anderson, KC
    BLOOD, 2004, 104 (13) : 4188 - 4193
  • [3] A review of the proteasome inhibitor bortezomib in multiple myeloma
    Richardson, PG
    EXPERT OPINION ON PHARMACOTHERAPY, 2004, 5 (06) : 1321 - 1331
  • [4] Proteasome inhibitor bortezomib for the treatment of multiple myeloma
    Cavo, M.
    LEUKEMIA, 2006, 20 (08) : 1341 - 1352
  • [5] Proteasome inhibitor bortezomib for the treatment of multiple myeloma
    M Cavo
    Leukemia, 2006, 20 : 1341 - 1352
  • [6] β-Catenin Inhibitor BC2059 Is Efficacious as Monotherapy or in Combination with Proteasome Inhibitor Bortezomib in Multiple Myeloma
    Savvidou, Ioanna
    Khong, Tiffany
    Cuddihy, Andrew
    McLean, Catriona
    Horrigan, Stephen
    Spencer, Andrew
    MOLECULAR CANCER THERAPEUTICS, 2017, 16 (09) : 1765 - 1778
  • [7] Bortezomib - first proteasome inhibitor for the treatment of multiple Myeloma
    Jurczyszyn, Artur
    Skotnicki, Aleksander B.
    WSPOLCZESNA ONKOLOGIA-CONTEMPORARY ONCOLOGY, 2007, 11 (03): : 112 - 124
  • [8] Combination of the mTOR inhibitor rapamycin and Revlimid™ (CC-5013) has synergistic activity in multiple myeloma (MM)
    Raje, N
    Kumar, S
    Hideshima, T
    Ishitsuka, K
    Chauhan, D
    Mitsiades, C
    Podar, K
    Le Gouill, S
    Richardson, P
    Munshi, NC
    Stirling, DI
    Antin, JH
    Anderson, KC
    BLOOD, 2004, 104 (11) : 417A - 417A
  • [9] Activity of panobinostat in combination with bortezomib and dexamethasone in advanced, proteasome inhibitor refractory multiple myeloma
    Petricevic B.
    Hilbe W.
    Zojer N.
    memo - Magazine of European Medical Oncology, 2017, 10 (3) : 159 - 163
  • [10] Proteasome inhibitor, bortezomib, for myeloma and lymphoma
    Tobinai, Kensei
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2007, 12 (05) : 318 - 326
12345